Our finding that blockade of the TLR4–NF-κB signalling pathway reversed skeletal muscle loss suggests a potential new strategy for clinical intervention in skeletal muscle weakness induced by endotoxemia and subsequent systemic inflammation. This evidence concerns the gene NFKB1 and serum lipopolysaccharide activity.